These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 20359812)

  • 21. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
    Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
    Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
    Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
    Brouwers AH; Mulders PF; Oyen WJ
    J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status and future directions of molecular markers in renal cell carcinoma.
    Rini BI
    Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.
    Tostain J; Li G; Gentil-Perret A; Gigante M
    Eur J Cancer; 2010 Dec; 46(18):3141-8. PubMed ID: 20709527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
    Lin XY; Zhang H; Tang N; Zhang XP; Zhang W; Wang EH; Han YC
    Histopathology; 2015 Apr; 66(5):685-94. PubMed ID: 25431204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
    Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
    Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbonic anhydrase IX: historical and future perspectives.
    Oosterwijk E
    BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
    [No Abstract]   [Full Text] [Related]  

  • 35. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
    Grabmaier K; A de Weijert MC; Verhaegh GW; Schalken JA; Oosterwijk E
    Oncogene; 2004 Jul; 23(33):5624-31. PubMed ID: 15184875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
    Leppert JT; Lam JS; Pantuck AJ; Figlin RA; Belldegrun AS
    BJU Int; 2005 Aug; 96(3):281-5. PubMed ID: 16042714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
    Ramsey ML; Yuh BJ; Johnson MT; Yeldandi AV; Zynger DL
    Virchows Arch; 2012 Jan; 460(1):89-93. PubMed ID: 22143934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker discovery in urogenital cancer.
    Said J
    Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
    Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
    PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.